Improving HPV vaccination rates among young girls in Nigeria
Official title: Implementation Penetration Assessment Criteria Tool for HPV Vaccination- Promoting Uptake among Young Girls in Nigeria
Funded at Washington University · NIH-10998613 · Data updated 2026-11-12
This study is looking at how to help more teenage girls in Nigeria get the HPV vaccine by figuring out what makes it easier or harder for them to get vaccinated in their communities.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | February 5, 2025 |
| Project end | February 4, 2027 |
| Funding year | 2024 |
| Award (this year) | $36,801 |
| NIH project number | 1F31CA294971-01 |
| Project ID | NIH-10998613 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescent girls and young women in Nigeria who are eligible for HPV vaccination.
✕Less likely to help
Patients outside of Nigeria or those who are not within the target age group for HPV vaccination may not benefit from this research.
What this research studies
This research aims to address the gap between available HPV vaccines and their uptake among adolescent girls in Nigeria. It focuses on developing tools to assess and enhance the integration of HPV vaccination into community practices and policies. By identifying key factors that influence vaccination penetration, the project seeks to create a framework that can be easily implemented in resource-limited settings. The approach involves understanding community dynamics and perceptions to promote better vaccination rates.
Why it matters
Potential benefit: If successful, this research could significantly increase HPV vaccination rates among young girls, leading to reduced cervical cancer incidence in the future.
How similar studies have gone: Similar research efforts in other regions have shown promise in improving vaccination rates through community engagement and tailored interventions.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Anikamadu, Onyekachukwu — Washington University
- Study coordinator: Anikamadu, Onyekachukwu
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.